2023
Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR)
Elgammal Y, Risinger M, Husami A, Walden J, Gupta S, Shah N, Boyer J, Abajas Y, Winstead M, Miller D, Vidal-Anaya V, Vlachos A, Lal A, Ritchey A, Lorsbach R, Zhang W, Kalfa T, Niss O. Congenital Dyserythropoietic Anemia Type II: An Update from the Congenital Dyseryhtropoietic Anemia Registry of North America (CDAR). Blood 2023, 142: 1079. DOI: 10.1182/blood-2023-189389.Peer-Reviewed Original ResearchIron overloadIneffective erythropoiesisCongenital dyserythropoietic anemiaBlood transfusionHepatic hemosiderosisHemolytic anemiaIron levelsFrequency of transfusionGDF-15 levelsWhole-genome sequencingSeverity of anemiaAge of diagnosisCDA IINatural history studiesBody iron levelsDeep intronic variantsCDA II patientsCDA type IIIntronic variantsAutosomal recessive diseaseBone marrow erythroblastsBM examinationFerritin ratioGDF-15Anemia severity
2009
The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study
Truong F, Smith BR, Stachurski D, Cerny J, Medeiros LJ, Woda BA, Wang A. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study. Leukemia Research 2009, 33: 1039-1046. PMID: 19232722, DOI: 10.1016/j.leukres.2009.01.012.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeCytopenic patientsFlow cytometricPredictive valueGroup 1 patientsGroup 2 patientsHematology outpatient clinicBone marrow aspirateNegative predictive valuePositive predictive valueFCM resultsMedian followMyelomonocytic maturationAbnormal cytogeneticsBM examinationBM diseaseClinical entityOutpatient clinicProspective studyMedical causesMorphological dysplasiaClinical managementMarrow aspiratesIdiopathic cytopeniaPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply